Aadi Bioscience, Inc. AADI
Institutional shares held
15.6 Million
15K
calls
3.1K
puts
Total value of holdings
$40.3M
$38K
calls
$8K
puts
Market Cap
$54.4M
21,016,800
Shares Out.
Institutional ownership
74.07%
# of Institutions
57
We take great care to ensure that the data presented and summarized in this overview for Aadi Bioscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AADI
View all-
Avoro Capital Advisors LLC New York, NY2.85MShares$7.38 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$5.99 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$5.44 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$4.79 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$2.97 Million1.96% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY818KShares$2.12 Million2.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.98 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC526KShares$1.36 Million1.41% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny456KShares$1.18 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY443KShares$1.15 Million1.39% of portfolio
Latest Institutional Activity in AADI
Top Purchases
Top Sells
About AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Insider Transactions at AADI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2025
|
Caley Castelein |
BUY
Grant, award, or other acquisition
|
Indirect |
1,666,000
+43.48%
|
$3,332,000
$2.4 P/Share
|
|
Mar 04
2025
|
Bryan Ball |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+33.02%
|
$200,000
$2.4 P/Share
|
|
Mar 04
2025
|
Baiteng Zhao |
BUY
Grant, award, or other acquisition
|
Indirect |
1,250,000
+50.0%
|
$2,500,000
$2.4 P/Share
|
|
Mar 03
2025
|
Bryan Ball |
SELL
Open market or private sale
|
Direct |
2,147
-2.04%
|
$4,294
$2.35 P/Share
|
|
Mar 03
2025
|
David James Lennon CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,690
-14.55%
|
$11,380
$2.35 P/Share
|
|
Mar 03
2025
|
Scott M. Giacobello CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,806
-10.49%
|
$5,612
$2.35 P/Share
|
|
Mar 01
2025
|
Bryan Ball |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.55%
|
-
|
|
Mar 01
2025
|
David James Lennon CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,250
+29.35%
|
-
|
|
Mar 01
2025
|
Scott M. Giacobello CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,750
+20.15%
|
-
|
|
Oct 03
2024
|
David James Lennon CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,689
-29.76%
|
$9,689
$1.94 P/Share
|
|
Oct 02
2024
|
David James Lennon CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
32,558
+50.0%
|
-
|
|
Sep 03
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
40,000
-3.3%
|
$40,000
$1.71 P/Share
|
|
Aug 05
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,652
-0.46%
|
$5,652
$1.34 P/Share
|
|
Aug 02
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
18,933
-1.53%
|
$18,933
$1.41 P/Share
|
|
Aug 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
15,415
-1.23%
|
$15,415
$1.5 P/Share
|
|
Jul 02
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
8,652
-0.69%
|
$8,652
$1.34 P/Share
|
|
Jul 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
31,348
-2.43%
|
$31,348
$1.45 P/Share
|
|
Jun 04
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
20,225
-1.54%
|
$20,225
$1.77 P/Share
|
|
Jun 03
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
19,775
-1.49%
|
$19,775
$1.81 P/Share
|
|
May 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
40,000
-2.92%
|
$40,000
$1.93 P/Share
|
Last 12 Months Summary
Buy / Acquisition
3.08M
Shares
From
6
Insiders
| Grant, award, or other acquisition | 3.02M shares |
|---|---|
| Exercise of conversion of derivative security | 60.6K shares |
Sell / Disposition
260K
Shares
From
4
Insiders
| Open market or private sale | 260K shares |
|---|